Novo Nordisk Pharma Ltd. (President & Representative Director: Keisuke Kotani; Head Office: Chiyoda-ku, Tokyo; hereinafter "Novo Nordisk Pharma") hereby announces the following personnel change.

Executive Personnel Change (Effective June 1, 2026)

Name New Position Previous Position

Yukako Akiyama Director —

Ms. Yukako Akiyama will continue to serve as General Manager of the Diabetes & Obesity Sales Division.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to overcome serious chronic diseases, building on our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk Pharma Ltd., the Japanese affiliate, was established in 1980. For more information, please visit our website.

www.novonordisk.co.jp

FACT BOX

  • Source: PR TIMES
  • Category: 人事